BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

884 related articles for article (PubMed ID: 32271431)

  • 41. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells.
    Guo J; Jin D; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Miao S; Xi S
    EBioMedicine; 2018 Sep; 35():204-221. PubMed ID: 30146342
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer.
    Shen Q; Xu Z; Xu S
    Int J Oncol; 2020 Oct; 57(4):967-979. PubMed ID: 32945379
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MiR-200c-3p and miR-485-5p overexpression elevates cisplatin sensitivity and suppresses the malignant phenotypes of non-small cell lung cancer cells through targeting RRM2.
    Liu Y; Zhang Y; Li Q; Xu R; Huang N
    Thorac Cancer; 2022 Jul; 13(13):1974-1985. PubMed ID: 35599447
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The PVT1/miR-216b/Beclin-1 regulates cisplatin sensitivity of NSCLC cells via modulating autophagy and apoptosis.
    Chen L; Han X; Hu Z; Chen L
    Cancer Chemother Pharmacol; 2019 May; 83(5):921-931. PubMed ID: 30859368
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hsa_circ_0096157 silencing suppresses autophagy and reduces cisplatin resistance in non-small cell lung cancer by weakening the Nrf2/ARE signaling pathway.
    Lu H; Kong J; Cai S; Huang H; Luo J; Liu L
    Mol Biol Rep; 2024 Jun; 51(1):703. PubMed ID: 38822881
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Circ_0004015 silencing represses cisplatin chemoresistance and tumor progression by reducing KLF8 in a miR-198-dependent manner in non-small cell lung cancer.
    Li Y; Yang X; Xiong X
    Genomics; 2022 Mar; 114(2):110294. PubMed ID: 35134495
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Circ_0000079 Decoys the RNA-Binding Protein FXR1 to Interrupt Formation of the FXR1/PRCKI Complex and Decline Their Mediated Cell Invasion and Drug Resistance in NSCLC.
    Chen C; Zhang M; Zhang Y
    Cell Transplant; 2020; 29():963689720961070. PubMed ID: 32951448
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Overexpression of
    Liu Z; Dang C; Xing E; Zhao M; Shi L; Sun J
    DNA Cell Biol; 2019 Nov; 38(11):1366-1373. PubMed ID: 31633393
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Downregulation of long non-coding RNA XIST inhibits cell proliferation, migration, invasion and EMT by regulating miR-212-3p/CBLL1 axis in non-small cell lung cancer cells.
    Qiu HB; Yang K; Yu HY; Liu M
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8391-8402. PubMed ID: 31646569
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Circular RNA PRMT5 confers cisplatin-resistance via miR-4458/REV3L axis in non-small-cell lung cancer.
    Pang J; Ye L; Zhao D; Zhao D; Chen Q
    Cell Biol Int; 2020 Dec; 44(12):2416-2426. PubMed ID: 32808744
    [TBL] [Abstract][Full Text] [Related]  

  • 52. miR-125b-5p upregulation by TRIM28 induces cisplatin resistance in non-small cell lung cancer through CREB1 inhibition.
    Tan Q; Ma J; Zhang H; Wu X; Li Q; Zuo X; Jiang Y; Liu H; Yan L
    BMC Pulm Med; 2022 Dec; 22(1):469. PubMed ID: 36476351
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2.
    Xie J; Yu F; Li D; Zhu X; Zhang X; Lv Z
    Tumour Biol; 2016 Jan; 37(1):1197-204. PubMed ID: 26282001
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
    Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
    Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Downregulation of N-Acetylglucosaminyltransferase GCNT3 by miR-302b-3p Decreases Non-Small Cell Lung Cancer (NSCLC) Cell Proliferation, Migration and Invasion.
    Li Q; Ran P; Zhang X; Guo X; Yuan Y; Dong T; Zhu B; Zheng S; Xiao C
    Cell Physiol Biochem; 2018; 50(3):987-1004. PubMed ID: 30355927
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGFβR1/Smad signaling pathway in NSCLC.
    Wang X; Chen X; Meng Q; Jing H; Lu H; Yang Y; Cai L; Zhao Y
    Sci Rep; 2015 Dec; 5():17618. PubMed ID: 26620926
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Circ_0020123 enhances the cisplatin resistance in non-small cell lung cancer cells partly by sponging miR-140-3p to regulate homeobox B5 (HOXB5).
    Wei D; Zeng J; Rong F; Xu Y; Wei R; Zou C
    Bioengineered; 2022 Mar; 13(3):5126-5140. PubMed ID: 35170372
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Knockdown of circLRWD1 weakens DDP resistance via reduction of SIRT5 expression through releasing miR-507 in non-small cell lung cancer.
    Deng Z; Tu Q; Hu G; Xing M
    Anticancer Drugs; 2022 Oct; 33(9):861-870. PubMed ID: 35946561
    [TBL] [Abstract][Full Text] [Related]  

  • 59. LncRNA GAS5 modulates the progression of non-small cell lung cancer through repressing miR-221-3p and up-regulating IRF2.
    Ma J; Miao H; Zhang H; Ren J; Qu S; Da J; Xu F; Zhao H
    Diagn Pathol; 2021 May; 16(1):46. PubMed ID: 34022918
    [TBL] [Abstract][Full Text] [Related]  

  • 60. GATA6 activated long non-coding RNA PCAT1 maintains stemness of non-small cell lung cancer by mediating FRK.
    Zang Q; Xu L; Li J; Jia H
    J BUON; 2020; 25(5):2371-2381. PubMed ID: 33277858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.